Last week's stock offering marked the second time this year thatBioMed has raised funds in a difficult capital markets environment.In April, the San Diego-based REIT raised $149.7 million. In bothofferings, BioMed said the funds would be used to pay down its lineof credit and cover general corporate uses.

One of the chief factors in BioMed's capacity to raise capitalin these uncertain times--and one of the reasons for its continuedstrong performance generally--was explained by Alan D. Gold, theREIT's president and CEO, during its latest conference call withfinancial analysts. "Despite a very turbulent macro-economicenvironment, the demand for life science real estate remainsrelatively strong," Gold said in the conference call.

BioMed has not yet reported results for the third quarter, whichended Sept. 30, but its results for the second quarter showed fundsfrom operations rising to $34.5 million from about $33 million insecond quarter 2007. Leasing volume grew to 327,000 sf from 127,000sf in the previous quarter. In reporting the results, Gold noted"our long-term, triple-net leased structures provide us with arelatively stable, steady and predictable cash flow stream."